"Johnson & Johnson (NYSE:JNJ) is a major healthcare company focused on innovative pharmaceuticals and medical devices. The company faces a critical transition as sales from its blockbuster drug Stelara begin to decline due to patent expiration. However, J&J is successfully executing on its strategy to offset these losses with a robust pipeline of new drugs, particularly in oncology and immunology. The stock responded positively in the quarter as the company demonstrated significant progress on multiple fron ...